Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.

M. Rosenzweig, Jose F. Ponte, Irina Apostolou, Daniel Doty, J. Guild, Michael Slavonic, Paul Ponath, Louis Vaickus

Journal of Clinical Oncology · 2010 · 20 citations · 0 references

Concepts

Abstract

e13028 Background: Glucocorticoid-induced tumor necrosis factor receptor (GITR) is expressed on several cell types, including regulatory and effector T cells, B cells, NK cells, and antigen-presenting cells. In murine models, our agonistic anti-mouse (m) GITR antibody was a robust vaccine adjuvant and, in combination with chemotherapy, significantly reduced tumor burden and prolonged survival compared with antibody or chemotherapy alone. The anti-mGITR Mab enhanced effector T cell responses and ablation of T regulatory cell-mediated suppression. A similar effect was observed when a chimeric anti-human (hu) GITR Mab (Ch-6C8-Agly) was used in nonhuman primates (NHP). NHP treated with anti-huGITR had augmented humoral and cellular immune responses compared with controls. Mab treatment was well tolerated with no observed adverse events. Methods: TRX518, a fully humanized IgG1 anti-huGITR Mab, was constructed. In addition to humanization, heavy chain asparagine 297 was substituted with alanine to eliminate N-linked glycosylation. This mutation abrogates Fc region functionality, including antibody-dependent cellular cytotoxicity and complement-mediated lysis. Further in vitro and in vivo characterization of TRX518 was conducted. Results: TRX518 bound to GITR on CD4+ and CD8+ naïve and memory T cells, B cells, NK cells, NKT cells, monocytes, and macrophages, yet was nondepleting. Though TRX518 costimulated suboptimally activated peripheral blood lymphocytes it was not a superagonist, as it did not induce proliferation by itself. Plate-bound TRX518 did not induce appreciable cytokine release (IL-2, IL-6, IL-10, TNFa, IFNg). TRX518 blocked the interaction of GITR with its ligand and enhanced the cytotoxicity of NK cells. However, it did not block an allogeneic mixed lymphocyte reaction (MLR) or enhance an autologous MLR. Cynomolgous macaque and human tissue cross studies and an IND-enabling GMP toxicology study are complete. Conclusions: TRX518 is a promising candidate for evaluation in human cancer indications. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Tolerx Tolerx